Kaufman Bros. Starts Conceptus (CPTS) at Hold; Balancing Sales & Marketing Programs Needed to Drive Growth as Patients Continue to Hide

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. NVDA
4. TSLA
5. USO
6. AWK
7. GNK
8. ARGX
9. FNGR
10. PLUR

September 22, 2011 7:30 AM EDT
Get Alerts CPTS Hot Sheet
Price: $31.02 --0%

Rating Summary:
    2 Buy, 11 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Kaufman Bros. initiates coverage on Conceptus (NASDAQ: CPTS) with a Hold. PT $11.00.

Kaufman analyst says, "On lingering softness in physician office visits, as well as tough competition from Hologic (Nasdaq: HOLX)(BUY), Conceptus invests in both offensive and defensive sales and marketing programs to drive negative-to-low-single digit revenue gains in 2011E-2013E, down from historic 25%+ increases, pressuring operating profit margin expansion. CPTS is also trading at a premium to comparable small cap MedTech growth averages vis-a-vis its now slower growth outlook."

For more ratings news on Conceptus click here and for the rating history of Conceptus click here.

Shares of Conceptus closed at $10.37 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage

Related Entities

Kaufman Bros.